Independent effects of nevirapine prophylaxis and HIV-1 RNA suppression in breast milk on early perinatal HIV-1 transmission

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 4, 2007, Pages 472-478

  Chung, Michael H ^a   Kiarie, James N ^b   Richardson, Barbra A ^a,c   Lehman, Dara A ^a,c   Overbaugh, Julie ^c   Njiri, Francis ^b   John Stewart, Grace C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b KENYATTA NATIONAL HOSPITAL   (Kenya)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Africa; Breast milk; HIV 1; Mother to child transmission; Nevirapine; Prevention of perinatal transmission

Indexed keywords

NEVIRAPINE; ZIDOVUDINE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BREAST MILK; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION RISK; MULTIVARIATE ANALYSIS; PERINATAL INFECTION; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; RNA ISOLATION; SINGLE DRUG DOSE; VIRUS SHEDDING; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KENYA; MILK, HUMAN; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RNA, VIRAL; SEXUAL BEHAVIOR; VIRAL LOAD;

EID: 36049014941     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181594c1c     Document Type: Article

References (24)

1. McIntyre J. Prevention of mother-to-child transmission of HIV: treatment options. Expert Review of Anti-infective Therapy. 2005;3:971-980.
2. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis. 2005;192:24-29.
3. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356:135-147.
4. Kuhn L, Sinkala M, Kankasa MP, et al. Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission. J Acquir Immune Defic Syndr. 2006;42:260-262.
5. Hammer SM. Single-dose nevirapine and drug resistance: the more you look, the more you find. J Infect Dis. 2005;192:1-3.
6. Shapiro RL, Thior I, Gilbert PB, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS. 2006;20:1281-1288.
7. Thistle P, Spitzer RF, Glazier RH, et al. A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe. Clin Infect Dis. 2007;44:111-119.
8. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis. 2001;183:206-212.
9. Manigart O, Crepin M, Leroy V, et al. Effect of perinatal zidovudine prophylaxis on the evolution of cell-free HIV-1 RNA in breast milk and on postnatal transmission. J Infect Dis. 2004;190:1422-1428.
10. Rousseau CM, Nduati RW, Richardson BA, et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis. 2003;187:741-747.
11. Chung MH, Kiarie JN, Richardson BA, et al. Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine. AIDS. 2005;19:1415-1422.
12. Muro E, Droste JA, Hofstede HT, et al. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Defic Syndr. 2005;39:419-421.
13. Gray GE, Urban M, Chersich MF, et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS. 2005;19:1289-1297.
14. Taha TE, Kumwenda NI, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet. 2003;362:1171-1177.
15. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
16. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet. 1999;353:773-780.
17. Panteleeff DD, John G, Nduati R, et al. Rapid method for screening dried blood samples on filter paper for human immunodeficiency virus type 1 DNA. J Clin Microbiol. 1999;37:350-353.
18. Dabis F, Bequet L, Ekouevi DK, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS. 2005;19:309-318.
19. Pillay K, Coutsoudis A, York D, et al. Cell-free virus in breast milk of HIV-1-seropositive women. J Acquir Immune Defic Syndr. 2000;24:330-336.
20. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005;38:283-288.
21. Eshleman SH, Hoover DR, Hudelson SE, et al. Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Infect Dis. 2006;193:479-481.
22. Rousseau CM, Nduati RW, Richardson BA, et al. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis. 2004;190:1880-1888.
23. Shapiro RL, Ndung'u T, Lockman S, et al. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis. 2005;192:713-719.
24. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants, Towards Universal Access: Recommendations for a Public Health Approach. Geneva, Switzerland: WHO Press; 2006.